Clinical Trial

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-12-23.
Trial Details
NCT Number NCT05678270
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Intrahepatic Cholangiocarcinoma (ICC)
Enrollment 70 participants
Start Date 2022-11-15
Primary Completion 2026-05 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-02-07